Our faculty research broadens the knowledge of kidney disease.
Strategies to Improve Patient Engagement in Young Kidney Transplant Recipients: A Review.
Young adult and adolescent kidney transplant recipients have shorter graft survival than older and younger recipients. Although multifactorial, the tendency toward premature graft loss in young kidney transplant recipients has often been attributed to medication nonadherence and the transition from pediatric to adult care.
Genetic Variants Associated with Circulating Fibroblast Growth Factor 23
Fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphorus and vitamin D metabolism, contributes to the pathogenesis of mineral and bone disorders in CKD and is an emerging cardiovascular risk factor. Central elements of FGF23 regulation remain incompletely understood; genetic variation may help explain interindividual differences.
Chronic kidney disease attenuates the plasma metabolome response to insulin
Chronic kidney disease (CKD) leads to decreased sensitivity to the metabolic effects of insulin, contributing to protein energy wasting and muscle atrophy. Targeted metabolomics profiling during hyperinsulinemic-euglycemic insulin clamp testing may help identify aberrant metabolic pathways contributing to insulin resistance in CKD.
Young Kidney Professionals' Perspectives and Attitudes about Consuming Scientific Information: A Focus Group Study
The digital era has seen rapid changes in how information is consumed. Traditional dissemination of scholarly work through biomedical journals may not be optimally tailored to the preferences of younger clinicians and researchers. We aimed to describe the perspectives of young clinicians and researchers in kidney disease on consuming scientific information. Three focus groups were conducted during the 2017 American Society of Nephrology Kidney Week with a total of 29 nephrologists and researchers (ages 40 years old and younger) purposively sampled through our networks and the American Society of Nephrology registration database. Data were analyzed thematically.
Complications of Immunosuppression in Glomerular Disease
This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.
Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: A Focus on Heart Failure
Although the population of patients with kidney disease and concurrent HF continues to grow, knowledge of HF therapies specifically in the CKD and ESKD population remains limited. This article will review known and emerging therapies for HF among patients with CKD and patients with ESKD, briefly summarize the implications of known and novel therapies on current clinical practice, and outline possible areas for further investigation.
Cells of NG2 lineage increase in glomeruli of mice following podocyte depletion
Under certain circumstances, podocytes can be partially replaced following their loss in disease. The inability of podocytes to proliferate suggests that replacement derives from other cell types.
Telehealth and Home Dialysis: A New Option for Patients in the United States
Telehealth and Home Dialysis
Location of glomerular immune deposits, not codeposition of immunoglobulin G, influences definitive renal outcomes in immunoglobulin A nephropathy
It has been suggested that the prognosis of immunoglobulin (IgA) nephropathy (IgAN) is adversely affected if there is codeposition of IgG in the glomeruli or if immune deposits are present in the glomerular capillary walls. We sought to understand how these variables affect clinical outcome.
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
To describe a systematic review process to reduce non-evidence-based inpatient use of high-cost medications across a large multi-hospital academic health system. We created a Pharmacy & Therapeutics subcommittee consisting of clinicians, pharmacists, and an ethics representative. This committee developed a standardized process for a timely review (<48 hours) and approval of high-cost medications based on their clinical effectiveness, safety, and appropriateness.